Catheter Precision Engages Strategic Advisor
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) engaged a strategic advisor on April 2, 2026 to formally market for sale its cardiac electrophysiology business. The process aims to monetize legacy medical device assets (LockeT and VIVO) that have FDA market clearance and the CE mark, while the company sharpens focus on its Flyte aviation platform. Management says the sale could unlock shareholder value and that monetization would position the company as a pure‑play aviation business through disciplined capital allocation and increased execution and transparency.
AI-generated analysis. Not financial advice.
Positive
- Strategic advisor engaged to market cardiac electrophysiology business (April 2, 2026)
- Regulatory clearances: LockeT and VIVO have FDA market clearance and CE mark
- Refocus to Flyte aviation platform aims to create a pure‑play aviation valuation
Negative
- No financial terms disclosed for the potential sale or expected proceeds
- Outcome uncertain: marketing process may not result in a sale or favorable valuation
News Market Reaction – VTAK
On the day this news was published, VTAK declined 1.06%, reflecting a mild negative market reaction. Argus tracked a peak move of +9.4% during that session. Argus tracked a trough of -19.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $27K from the company's valuation, bringing the market cap to $2.53M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
VTAK traded down 6.93% while momentum data show 3 medical-device peers (e.g., NUWE, AMIX, AEMD) moving up with a median gain near 2.7%. That divergence points to company-specific dynamics around VTAK rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Full-year results | Positive | -3.8% | 2025 results and strategic expansion update with strong growth but losses. |
| Mar 25 | Aviation expansion | Positive | -4.2% | Flyte Hops Vision Jet platform expansion and growth plans in private aviation. |
| Mar 16 | Route expansion | Positive | +4.4% | Launch of Flyte Hops Florida and stronger inbound bookings on regional routes. |
| Mar 11 | Financing & growth | Positive | -7.0% | Up to $88M in institutional financing commitments and Flyte acquisition closing. |
| Mar 10 | Acquisition deal | Positive | +25.6% | Definitive merger to acquire remaining Flyte stake, consolidating aviation platform. |
Recent VTAK news has often been positive strategically, with mixed price reactions and several selloffs on ostensibly constructive updates.
Over the past month, VTAK has transitioned from a pure cardiac electrophysiology story toward a dual-platform, then aviation-focused narrative. On Mar 10, it completed the Flyte acquisition, which saw a 25.55% gain. Subsequent financings and growth plans on Mar 11 and aviation expansion updates on Mar 16 and Mar 25 brought both rallies and pullbacks. Full‑year 2025 results on Mar 31 paired strong revenue growth with sizable losses. Today’s plan to market the cardiac business for sale fits this ongoing portfolio realignment toward Flyte.
Market Pulse Summary
This announcement outlines a plan to market VTAK’s cardiac electrophysiology business, including LockeT and VIVO, to larger medical device companies while sharpening focus on the Flyte aviation platform. Both devices already hold FDA market clearance and the CE mark, positioning them as saleable legacy assets. In recent months, VTAK has layered on Flyte acquisitions, financings, and route expansions, so investors may watch deal terms, execution on any divestiture, and progress toward a pure-play aviation valuation framework.
Key Terms
cardiac electrophysiology medical
ventricular mapping medical
fda market clearance regulatory
ce mark regulatory
interventional radiology medical
AI-generated analysis. Not financial advice.
Goal to unlock value in cardiac electrophysiology assets Strategic process to include outreach to leading global medical device companies
FORT MILL, S.C., April 02, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that it has engaged a strategic advisor to formally market for sale its cardiac electrophysiology business. This strategic initiative is designed to create shareholder value by monetizing the Company’s legacy medical device assets while sharpening its focus on the high-growth Flyte aviation platform.
David Jenkins, CEO of VTAK, commented, “We believe that our cardiac electrophysiology portfolio may provide significant value to larger, better capitalized, companies than our own that is not reflected in our own company’s current market capitalization. Both LockeT and VIVO are being used by surgical and recovery teams in many hospitals in the U.S. and internationally including leading teaching hospitals. We believe LockeT provides multiple competitive advantages including large-bore closure capability, cross-functional applications spanning electrophysiology, structural heart, and interventional radiology, and lower cost per procedure. Both our product lines of LockeT and VIVO, our ventricular mapping product, have now gained FDA market clearance as well as the CE mark. With the infrastructure of a larger strategic acquirer, these assets have the potential to have their usage significantly increase within the broader cardiovascular industry. We look forward to the potential value that this strategic process may bring to our shareholders.”
Mr. Jenkins continued, “By separating and monetizing these assets, we believe that over time our company will become valued in the stock market as a pure-play aviation business. Our objective is straightforward- drive shareholder value through execution, transparency, and disciplined capital allocation.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
